carboxymethyltriphenylphosphonium bromide | 1530-44-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carboxymethyltriphenylphosphonium bromide
• 英文别名: Carboxymethyl triphenylphosphonium bromide；carboxymethyl(triphenyl)phosphanium;bromide
• CAS: 1530-44-5
• 化学式: Br*C₂₀H₁₈O₂P
• 分子量: 401.239
• InChiKey: UMPZROCPMSJJNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  carboxymethyltriphenylphosphonium bromide 、 2-萘甲醛 在 dimsyl sodium 作用下， 生成 3-(2-naphthyl)acrylic acid
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  溴乙酸 、 三苯基膦 以 甲苯 为溶剂， 反应 24.0h， 生成 carboxymethyltriphenylphosphonium bromide
  参考文献：
  名称：

  官能化phospho基离子液体可作为由过氧化物和二氧化碳合成环状碳酸酯的有效催化剂

  摘要：

  通过一种简单的方法合成了一系列新颖的功能化phospho基离子液体（FPBIL），并首先评估了在不存在助催化剂和溶剂的情况下，通过将CO 2环化成环氧化物来合成环状碳酸酯的催化剂。FPBIL在环加成反应中表现良好，尤其是羧基官能化反应。在[Ph 3 PC 2 H 4 COOH] Br上，碳酸亚丙酯在130°C和3小时内在2.5 MPa下的产率为97.3％（TOF = 64.9 h -1）。偏振的协同作用通过氢键和Br的亲核攻击诱导的-负离子具有出色的性能。此外，具有中等亚甲基链长的FPBIL显示出优异的催化活性。这是因为它们在strong阳离子和卤化物阴离子之间具有强酸性和弱的静电相互作用。强酸性有利于化环氧的开环和弱静电相互作用增强BR的亲核攻击能力- 。可以设想，无金属和无溶剂工艺具有将CO 2催化转化为增值化学品的高潜力。

  DOI：

  10.1016/j.apcata.2013.10.060

文献信息

• Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as <i>N</i>-acylethanolamine acid amidase (NAAA) inhibitors
  作者：Pan Zhou、Lei Xiang、Dongsheng Zhao、Jie Ren、Yan Qiu、Yuhang Li

  DOI：10.1039/c8md00432c

  日期：——

  N-Acylethanolamine acid amidase (NAAA) is one of the key enzymes involved in the degradation of fatty acid ethanolamides (FAEs), especially for palmitoylethanolamide (PEA). Pharmacological blockage of NAAA restores PEA levels, providing therapeutic benefits in the management of inflammation and pain. In the current work, we showed the structure-activity relationship (SAR) studies for pyrrolidine amide

  N-酰基乙醇胺酸酰胺酶（NAAA）是参与脂肪酸乙醇酰胺（FAE）降解的关键酶之一，尤其是对于棕榈酰乙醇酰胺（PEA）而言。NAAA的药理学阻断作用可恢复PEA水平，从而在炎症和疼痛的治疗中提供治疗益处。在当前的工作中，我们显示了吡咯烷酰胺衍生物作为NAAA抑制剂的结构-活性关系（SAR）研究。检查了吡咯烷酰胺的末端苯基的一系列芳族取代基或取代基。SAR数据表明，较小的亲脂性3-苯基取代基对于最佳效用是优选的。构象柔性的接头增加了吡咯烷酰胺衍生物的抑制能力，但降低了其对脂肪酸酰胺水解酶（FAAH）的选择性。构象上受限的接头没有增强抑制剂对NAAA的效力，但是改善了对FAAH的选择性。开发了几种低微摩尔有效的NAAA抑制剂，其中包括带有刚性4-苯基肉桂酰基的4g。透析和动力学分析表明4g通过竞争和可逆的机制抑制NAAA。此外，4g在脂多糖（LPS）诱导的急性肺损伤（ALI）模型中显示出较高的抗
• [EN] ESTROGEN RECEPTOR IMAGING AGENTS<br/>[FR] AGENTS D'IMAGERIE D'UN RÉCEPTEUR DES ŒSTROGÈNES
  申请人：UNIV NORTHEASTERN

  公开号：WO2014093378A1

  公开（公告）日：2014-06-19

  Compounds useful for molecular imaging of cells expressing estrogen receptors are provided. Also provided are intermediates for making the compounds and methods of making the compounds using a modular convergent strategy. Further, methods of making the intermediates are described, as well as methods of diagnosing disease in a subject by using the compounds as imaging agents.

  提供了用于分子成像表达雌激素受体的细胞的化合物。还提供了用于制备这些化合物的中间体以及使用模块收敛策略制备这些化合物的方法。此外，描述了制备这些中间体的方法，以及使用这些化合物作为成像剂在受试者中诊断疾病的方法。
• Heterocyclic compounds
  申请人：Zeneca Limited

  公开号：US05866568A1

  公开（公告）日：1999-02-02

  The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  该发明涉及具有以下式I的药用化合物，其中A.sup.1、A.sup.2、A.sup.3、A.sup.4、B.sup.1、m、Ar、W、X、Y、Z和R.sup.1具有本文中定义的任何含义，以及它们的药用盐和含有它们的药物组合物。这些新颖化合物具有内皮素受体拮抗活性，例如，在治疗内皮素水平升高或异常对疾病或医疗状况起重要致因作用的情况下是有用的。该发明还涉及制造这些新颖化合物的过程以及在医疗治疗中使用这些化合物的方法。
• Enantioselective Total Synthesis of (+)-Monocerin, a Dihydroisocoumarin Derivative with Potent Antimalarial Properties
  作者：Arun K. Ghosh、Daniel S. Lee

  DOI：10.1021/acs.joc.9b00414

  日期：2019.5.17

  We describe here the enantioselective synthesis of (+)-monocerin and its acetate derivative. The present synthesis features an efficient optically active synthesis of the β-hydroxy-γ-lactone derivative with high enantiomeric purity using Sharpless dihydroxylation as the key step. The synthesis also highlights a tandem Lewis acid-catalyzed, oxocarbenium ion-mediated diastereoselective syn-allylation

  我们在这里描述了 (+)-monocerin 及其乙酸酯衍生物的对映选择性合成。本合成的特点是使用 Sharpless 二羟基化作为关键步骤，高效光学活性合成具有高对映体纯度的 β-羟基-γ-内酯衍生物。该合成还强调了串联路易斯酸催化、氧碳鎓离子介导的非对映选择性顺烯丙基化反应，以及甲氧基甲基促进的亚甲基化反应。我们用各种路易斯酸研究了该反应。CrO3 介导的选择性氧化异色满提供了相应的内酯衍生物。该合成非常有效，可用于衍生物的制备。
• Substituted imidazoles
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20030181479A1

  公开（公告）日：2003-09-25

  The present invention relates to novel substituted imidazoles, to the use of these compounds as medicaments, to pharmaceutical compositions comprising the compounds, and to a method of treatment employing these compounds and compositions. The present compounds show a high and selective binding affinity to the histamine H3 receptor indicating a histamine H3 receptor antagonistic or agonistic activity. As a result, the compounds are useful for the treatment of disorders related to the histamine H3 receptor. More particularly, the present compounds possess a histamine H3 receptor agonistic activity and are accordingly useful in the treatment of disorders in which a histamine H3 receptor activation is beneficial.

  本发明涉及新型取代咪唑，以及这些化合物作为药物的使用，包括含有这些化合物的制药组合物和使用这些化合物和组合物的治疗方法。这些化合物表现出高度选择性的结合亲和力，指示组合物具有组胺H3受体拮抗或激动活性。因此，这些化合物可用于治疗与组胺H3受体有关的疾病。更具体地，这些化合物具有组胺H3受体激动活性，因此可用于治疗组胺H3受体激活有益的疾病。